News on Roger Aeschbacher from BioPortfolio.com http://www.BioPortfolio.com Consolidated Roger Aeschbacher news from BioPortfolio.com Wed, 10 Feb 2010 02:08:49 GMT en New Procedure May Have Breast Cancer Patients Saying Bravahttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039277&HITNO=0&MSIZE=453&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Roger%20Aeschbacher&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039277&THISHREF=http://c.moreover.com/click/here.pl%3fz2537997560%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039277&HITNO=0&MSIZE=453&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Roger%20Aeschbacher&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039277&THISHREF=http://c.moreover.com/click/here.pl%3fz2537997560%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNBC Miami: New Procedure May Have Breast Cancer Patients Saying Bravahttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4038936&HITNO=1&MSIZE=453&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Roger%20Aeschbacher&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4038936&THISHREF=http://c.moreover.com/click/here.pl%3fz2537841663%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4038936&HITNO=1&MSIZE=453&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Roger%20Aeschbacher&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4038936&THISHREF=http://c.moreover.com/click/here.pl%3fz2537841663%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNBC Miami: Denosumab Demonstrated Superiority Over Zometa in Pivotal Phase 3 Head-to-Head Trial in Prostate Cancer Patienhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4038826&HITNO=2&MSIZE=453&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Roger%20Aeschbacher&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4038826&THISHREF=http://c.moreover.com/click/here.pl%3fz2537788458%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4038826&HITNO=2&MSIZE=453&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Roger%20Aeschbacher&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4038826&THISHREF=http://c.moreover.com/click/here.pl%3fz2537788458%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharma Live: Herbal medicines can be lethal, pathologist warnshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4038372&HITNO=3&MSIZE=453&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Roger%20Aeschbacher&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4038372&THISHREF=http://c.moreover.com/click/here.pl%3fz2537583879%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4038372&HITNO=3&MSIZE=453&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Roger%20Aeschbacher&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4038372&THISHREF=http://c.moreover.com/click/here.pl%3fz2537583879%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comEurekAlert!: Herbal medicines can be lethalhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034013&HITNO=4&MSIZE=453&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Roger%20Aeschbacher&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034013&THISHREF=http://c.moreover.com/click/here.pl%3fz2535559685%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034013&HITNO=4&MSIZE=453&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Roger%20Aeschbacher&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034013&THISHREF=http://c.moreover.com/click/here.pl%3fz2535559685%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comAnasthesia UK: Herbal medicines can be lethalhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033983&HITNO=5&MSIZE=453&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Roger%20Aeschbacher&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033983&THISHREF=http://c.moreover.com/click/here.pl%3fz2535531455%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033983&HITNO=5&MSIZE=453&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Roger%20Aeschbacher&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033983&THISHREF=http://c.moreover.com/click/here.pl%3fz2535531455%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comFrca.co.uk: Amgen announces results from Phase III trial of denosumab versus Zometahttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4037852&HITNO=6&MSIZE=453&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Roger%20Aeschbacher&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4037852&THISHREF=http://c.moreover.com/click/here.pl%3fz2537332400%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4037852&HITNO=6&MSIZE=453&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Roger%20Aeschbacher&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4037852&THISHREF=http://c.moreover.com/click/here.pl%3fz2537332400%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTherapeutics Daily: Amgen: Denosumab demonstrates superiority over Zometahttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4037296&HITNO=7&MSIZE=453&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Roger%20Aeschbacher&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4037296&THISHREF=http://c.moreover.com/click/here.pl%3fz2537015022%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4037296&HITNO=7&MSIZE=453&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Roger%20Aeschbacher&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4037296&THISHREF=http://c.moreover.com/click/here.pl%3fz2537015022%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comFierceBiotech: TomoTherapy Enters Australian Market With Purchase by Royal Brisbane & Women's Hospitalhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4036388&HITNO=8&MSIZE=453&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Roger%20Aeschbacher&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4036388&THISHREF=http://c.moreover.com/click/here.pl%3fz2536594943%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4036388&HITNO=8&MSIZE=453&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Roger%20Aeschbacher&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4036388&THISHREF=http://c.moreover.com/click/here.pl%3fz2536594943%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comFreshnews.com: Denosumab Demonstrated Superiority Over Zometa(R) In Pivotal Phase 3 Head-to-Head Trial In Prostate Cancer Patients With Bone Metastaseshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4035514&HITNO=9&MSIZE=453&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Roger%20Aeschbacher&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4035514&THISHREF=http://c.moreover.com/click/here.pl%3fz2536269434%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4035514&HITNO=9&MSIZE=453&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Roger%20Aeschbacher&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4035514&THISHREF=http://c.moreover.com/click/here.pl%3fz2536269434%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comMedical News Today: TomoTherapy Enters Australian Market With Purchase by Royal Brisbane & Women's Hospitalhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4035396&HITNO=10&MSIZE=453&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Roger%20Aeschbacher&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4035396&THISHREF=http://c.moreover.com/click/here.pl%3fz2536226257%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4035396&HITNO=10&MSIZE=453&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Roger%20Aeschbacher&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4035396&THISHREF=http://c.moreover.com/click/here.pl%3fz2536226257%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comFreshnews.com: Amgen's Phase III cancer trial meets endpointshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4035114&HITNO=11&MSIZE=453&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Roger%20Aeschbacher&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4035114&THISHREF=http://c.moreover.com/click/here.pl%3fz2536119433%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4035114&HITNO=11&MSIZE=453&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Roger%20Aeschbacher&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4035114&THISHREF=http://c.moreover.com/click/here.pl%3fz2536119433%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTradingMarkets: Amgen: Third clinical trial shows denosumab beats Zometahttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034646&HITNO=12&MSIZE=453&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Roger%20Aeschbacher&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034646&THISHREF=http://c.moreover.com/click/here.pl%3fz2535904424%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034646&HITNO=12&MSIZE=453&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Roger%20Aeschbacher&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034646&THISHREF=http://c.moreover.com/click/here.pl%3fz2535904424%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comMarketWatch: Amgen: Third clinical trial shows denosumab beats Zometahttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034644&HITNO=13&MSIZE=453&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Roger%20Aeschbacher&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034644&THISHREF=http://c.moreover.com/click/here.pl%3fz2535904170%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034644&HITNO=13&MSIZE=453&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Roger%20Aeschbacher&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034644&THISHREF=http://c.moreover.com/click/here.pl%3fz2535904170%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comMarketWatch: Denosumab Demonstrated Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Prostate Cancer Patients With Bone Metastaseshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034076&HITNO=14&MSIZE=453&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Roger%20Aeschbacher&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034076&THISHREF=http://c.moreover.com/click/here.pl%3fz2535604743%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034076&HITNO=14&MSIZE=453&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Roger%20Aeschbacher&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034076&THISHREF=http://c.moreover.com/click/here.pl%3fz2535604743%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comKansas City Business Journal: